Oxular

2 x Triesence® doses; nearly one year of response

Oxular’s Senior Medical Advisor, Prof. Marc de Smet, presented on “Managing CME via the Suprachoroidal Space” at the December 2021 IOIS Conference. His talk included an update on a hard-to-treat postsurgical macular edema patient. The Oxulumis® posterior suprachoroidal microcatheter was used under compassionate use for the administration of Triesence®, an approved triamcinolone acetonide suspension. The …

2 x Triesence® doses; nearly one year of response Read More »

Drug Delivery OIS presentation

Oxular’s Chief Scientific Officer, Ron Yamamoto, shared an overview of Oxular’s drug delivery formulations at the OIS Drug Delivery meeting. You can watch the entire talk below, to find out more about our long-lasting drug formulations – including a first look at our micelle technology designed for targeted, local delivery of chemotherapeutic agents in the …

Drug Delivery OIS presentation Read More »

Oxular presents at Eyecelerator

Our CEO, Tom Cavanagh, presented an overview of Oxular’s retinal therapeutics platform at Eyecelerator, during AAO 2021. It was a pleasure to share this update, with a specific focus on OXU-001, Oxular’s lead program investigating a long-lasting, suprachoroidally administered treatment for DME. You can read Tom’s presentation below. Play Previous Next

Oxular in Retina Today

Oxular was mentioned in this great article by Dr. Sivaprasad in Retina Today, on the promise of reduced treatment burden for DME patients via sustained-release steroids. Oxular is a key innovator in long-lasting retinal treatments and precise suprachoroidal space delivery, and some of the advantages behind our approach are highlighted here. Simply put, we believe …

Oxular in Retina Today Read More »

Oxular raises $37 million

Led by specialist life sciences investor, Forbion Investment will fund Phase 2 human clinical studies evaluating Oxular’s 12-month treatment for diabetic macular edema, and accelerate development of early-product pipeline   OXFORD, UK, 1 March 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announced that it has completed a $37 million (£27 million) …

Oxular raises $37 million Read More »

Dr. Jatinder Kapur appointed as VP of Quality

Appointment builds Oxular’s team as it prepares to enter human clinical studies evaluating OXU-001 OXFORD, UK, 8 February 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces that it has appointed Dr. Jatinder Kapur as Vice President of Quality. His primary responsibilities include establishing and managing the Company’s Quality Management System, …

Dr. Jatinder Kapur appointed as VP of Quality Read More »

Dr. Rafiq Hasan appointed as Non-Executive Director

Oxular Limited Appoints Dr. Rafiq Hasan as Non-Executive Director OXFORD, UK, 5 October 2020 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces it has appointed Dr. Rafiq Hasan as a Non-Executive Director of the Company. Dr. Hasan gained his medical degree in London and has pursued a highly successful career in …

Dr. Rafiq Hasan appointed as Non-Executive Director Read More »

David Fellows appointed as Chairman of the Board

David Fellows appointed as Chairman of Oxular’s Board of Directors David has more than 30 yearsof experience in various leadership roles within the ophthalmic pharmaceuticalindustry 10 January 2017 – Oxular Limited, the Oxford-based retinal therapeutics company, today announces the appointment of David Fellows, previously Non-Executive Director, as the Company’s Chairman of the Board. Mr. Fellows …

David Fellows appointed as Chairman of the Board Read More »

OBN Awards 2016 –Winners Recognised at Industry Leading Event

Abingdon, UK, 7 October 2016 – OBN Ltd, the membership organisation supporting the UK’s innovative life sciences companies, are delighted to announce the winners of the prestigious OBN Awards 2016 that were presented last night in front of a sold-out audience of over 250 leaders from Biotech, Medtech and Investment companies at the Town Hall …

OBN Awards 2016 –Winners Recognised at Industry Leading Event Read More »

Scroll to Top